Testing effectiveness (Phase 2)Study completedNCT02383927
What this trial is testing
Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations
Who this might be right for
Thyroid CancerSquamous Cell Carcinoma Head and Neck Cancer (HNSCC)HRAS Mutant Tumor+1 more
Kura Oncology, Inc. 63